Skip to content

Validation Study for Disability Assessment Functional of Patients With Inflammatory Diseases Intestinal Chronic (VALIDate)

IBD-Disk Validation Study for Disability Assessment Functional of Patients With Inflammatory Diseases Intestinal Chronic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03590639
Acronym
VALIDate
Enrollment
400
Registered
2018-07-18
Start date
2018-04-23
Completion date
2020-04-16
Last updated
2020-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

Inflammatory Bowel Diseases, disability, quality of life, IBD Disk, IBD-Disability Index, Patient-Reported Outcomes

Brief summary

Inflammatory Bowel Diseases (IBD) often affect psychological, family, social and professional dimensions of patients' life, leading to disability which is essential to quantify as part of Patient-Reported Outcomes (PROs) newly included in the therapeutic targets to reach in IBD patients. Up to now, the IBD-Disability Index (IBD-DI) was the only validated tool to assess functional status, but it is not appropriate for use in clinical practice. The IBD Disk was then developed, a shortened and self-administered tool, adapted from the IBD-DI, in order to give immediate representation of patient-reported disability. However, the IBD Disk has not been validated yet in clinical practice. The aims of the VALIDate study is to validate this tool in a large population of French IBD patients and to compare it to the already validated IBD-DI.

Detailed description

The IBD-Disk has not been evaluated in clinical practice and has not yet been validated. but the interest of rapid assessment of the disease led the physicians in University Hospital of Nantes' department, some of whom had participated in the construction of this tool, to use it in routine practice for consultations of patients with IBD, joined by many gastroenterologists from other hospitals including the University Hospitals of Rennes and Angers. The objective of this study is to validate this tool and prove its effectiveness by comparing it to the gold standard represented by the IBD-DI, in the same way that the PsoDisk has been validated prospectively compared to other tools for evaluating the quality of life and activity of psoriatic disease.

Interventions

None listed

Sponsors

University Hospital, Angers
CollaboratorOTHER_GOV
Rennes University Hospital
CollaboratorOTHER
Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients of both sexes * aged over 18 with an established diagnosis of IBD (Crohn's Disease, Ulcerative Colitis or IBD unclassified)

Exclusion criteria

* ongoing pregnancy or breast feeding woman * vulnerable people i.e. Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard ) * insufficient command of French language and relevant psychiatric comorbidities (both of them making the self-questionnaire difficult to fill in) * uncertain IBD diagnosis

Design outcomes

Primary

MeasureTime frameDescription
IBD Disk's validitychanges from baseline IBD disk at 12 monthsValidity of the questionnaire

Secondary

MeasureTime frameDescription
IBD Disk's reliabilityBaseline and follow-up visit (between 3 and 12 months after baseline) for all of the outcome measures, except for reproducibility (7 days after baseline)IBD Disk's reliability (Cronbach's coefficient alpha)
IBD Disk's reproducibilityBaseline and follow-up visit (between 3 and 12 months after baseline) for all of the outcome measures, except for reproducibility (7 days after baseline)IBD Disk's reproducibility (test-retest reliability)
Satisfaction of the physician by Visual analog ScaleBaseline and follow-up visit (between 3 and 12 months after baseline) for all of the outcome measures, except for reproducibility (7 days after baseline)IBD Disk's feasibility (visual analog scale filled by the physician at the end of the study)
Correlation between the IBD-Disk and the seriousness of the pathologyBaseline and follow-up visit (between 3 and 12 months after baseline) for all of the outcome measures, except for reproducibility (7 days after baseline)the IBD-disk will be combined to the seriousness of the disease.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026